Quick updates from the concall today:
Ambition: to have best EBITDA margins in India.
Changes in domestic business (one time correction): some hygiene initiatives (stopped bonus offers).
Abilify: 6% share in Sep data. Some customers do not report data.
On a contracted basis, estimate close to 15% share.
350-400 million tablets. Next 12 months high favourable.
H2: share could be a bit lower.
Nexium: more than 6 players in US market. Large attractive market.
Manufacturing intense. Target to have high single digit market share.
Shelcal: expect price rise 10% in November. 45% growth in volume terms.
Detrol: next 12 months – 3 more players to come in.
Long term loan 2200 cr. No plan to reduce LT debt in near future.
Brazil: impact due to currency devaluation. 10% growth in value terms.
Steps taken to mitigate:
1. Work on pricing (Improve)
2. Work on cost base (decrease)
3. Distributor margin (reduce)
Foreign exchange gain on net basis.
Receivables: Outstanding now 3 months and 9 days as compared to 4 months earlier
Inventory level is low.
ANDA filing: no filing this quarter.
Close to 20 products filed. Out of these expect 5-6 launches in next two years with limited competition.
Dahej facility: expect production/shipment to start before Xmas.
Expect increase in European tender business
European market:
Germany: main business in Europe. 16% growth in constant currency terms.
UK & Romania: short term slowdown.
Focus remains on Germany and UK.
Portfolio Derma close to 70 crore. Number 1 in face wash category.
| Subscribe To Our Free Newsletter |
